生物制药和疫苗的预测稳定性:加速患者获取的前景和建议
Daniel Skomski1, Andrea Ji2, Drago Kuzman3
1Merck & Co., Inc., Analytical R&D, 126 E Lincoln Ave, Rahway, New Jersey, USA.
Journal of pharmaceutical sciences
|June 14, 2025
概括
预测稳定性建模提供了一种科学方法来评估生物疗法保质期,可能加速药物开发并提高产品质量. 这种方法有助于公司在临床试验和市场应用的不断变化的行业准则中进行导航.
科学领域:
- 制药科学 制药科学
- 计算生物学 计算生物学
- 生物技术是生物技术.
背景情况:
- 生物治疗药物和疫苗需要严格的稳定性评估来确定长期的疗效和安全性.
- 传统的稳定性测试方法可能耗时且昂贵,可能会延迟市场准入.
- 不断变化的行业准则需要先进的稳定性评估方法.
研究的目的:
- 审查预测稳定性的计算建模和基于风险的策略,以评估生物治疗药物的保质期.
- 讨论新的监管观点及其对临床试验和市场应用的影响.
- 探索新兴技术和行业采用预测稳定性的方法.
主要方法:
- 讨论预测稳定性的计算建模技术.
- 应用基于科学风险的方法来评估保质期.
- 对关键质量属性的案例研究进行分析.
- 解释模型方法,复杂性和缓解策略.
- 在稳定性评估中纳入新兴技术.
主要成果:
- 预测稳定性建模为评估长期稳定性提供了前性方法.
- 新的监管方法正在出现,影响行业实践.
- 全行业调查数据揭示了生物制药公司如何适应.
- 案例研究证明了这些模型对关键质量属性的应用.
结论:
- 预测稳定性建模显示,在加速患者获得药物的过程中,有显著的前景.
- 这种方法可以克服药物开发中的与稳定性相关的瓶.
- 提高科学理解和产品的稳定性是关键的好处.
- 采用这些方法对于导航不断变化的生物制药领域至关重要.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Sensitivity, Specificity, and Predicted Value
228
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Sensitivity is the...
228
Analysis of Population Pharmacokinetic Data
241
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
241
Pharmacovigilance
795
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
795
Bioequivalence: Overview
949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
Vaccinations
44.2K
Overview
44.2K


